Ascendis Pharma A/S
ASND
$158.54
-$2.98-1.85%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 10.59% | 35.98% | 117.21% | 171.64% | 337.71% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.59% | 35.98% | 117.21% | 171.64% | 337.71% |
| Cost of Revenue | 13.18% | -0.41% | 66.65% | 90.87% | 293.20% |
| Gross Profit | 10.16% | 43.26% | 129.68% | 192.51% | 346.20% |
| SG&A Expenses | 21.41% | 10.07% | 8.46% | 8.93% | 14.60% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.59% | -11.10% | -9.16% | -0.57% | 9.63% |
| Operating Income | 8.49% | 38.61% | 43.31% | 36.63% | 34.76% |
| Income Before Tax | 32.06% | 21.15% | 28.50% | 17.05% | 7.87% |
| Income Tax Expenses | -60.39% | -33.24% | 45.59% | 59.21% | 38.46% |
| Earnings from Continuing Operations | 32.53% | 21.33% | 27.68% | 16.30% | 7.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 32.53% | 21.33% | 27.68% | 16.30% | 7.35% |
| EBIT | 8.49% | 38.61% | 43.31% | 36.63% | 34.76% |
| EBITDA | 8.55% | 39.73% | 44.46% | 37.72% | 35.90% |
| EPS Basic | 34.74% | 22.97% | 28.91% | 17.37% | 8.25% |
| Normalized Basic EPS | 34.27% | 22.80% | 29.72% | 18.11% | 8.76% |
| EPS Diluted | 34.74% | 22.97% | 28.91% | 17.37% | 8.25% |
| Normalized Diluted EPS | 34.27% | 22.80% | 29.72% | 18.11% | 8.76% |
| Average Basic Shares Outstanding | 3.87% | 2.85% | 1.69% | 1.33% | 1.01% |
| Average Diluted Shares Outstanding | 3.87% | 2.85% | 1.69% | 1.33% | 1.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |